Revolution Medicines, Inc. (NASDAQ: RVMD) has announced positive updates from its clinical trials of RMC-6236, a drug targeting RAS-addicted cancers, showing promising results in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The data from Phase 1 and Phase 1b studies indicate that RMC-6236, both as a monotherapy and in combination, offers potential benefits for patients with these difficult-to-treat cancers.
RMC-6236 Monotherapy in Pancreatic Cancer
RMC-6236 demonstrated encouraging safety and efficacy as a monotherapy in patients with second-line metastatic PDAC. The treatment was generally well-tolerated, with mild rash and gastrointestinal issues being the most common adverse events. Notably, patients with a specific KRAS G12X mutation achieved a median progression-free survival (PFS) of 8.8 months. The objective response rate (ORR) in this group was 36%.
RMC-6236 in Non-Small Cell Lung Cancer
In NSCLC, data up to September 30, 2024, showed that RMC-6236 was generally well-tolerated at doses up to 220 mg daily. Patients who had previously undergone immunotherapy and platinum chemotherapy, but not docetaxel, achieved a median PFS of 9.8 months and an ORR of 38%.
Combination Studies and Future Plans
Combination studies of RMC-6236 with pembrolizumab, an immunotherapy drug, were also well-tolerated in NSCLC patients. Additionally, a novel combination of RMC-6236 with another RAS(ON) inhibitor, RMC-6291, showed initial antitumor activity in heavily pretreated colorectal cancer patients, suggesting the potential of a doublet treatment strategy.
Revolution Medicines plans to advance RMC-6236 into earlier lines of therapy for metastatic PDAC and expects to initiate a Phase 3 clinical trial for NSCLC in the first quarter of 2025. These trials aim to provide new treatment options for patients with RAS-addicted cancers, which are often challenging to treat effectively.
The company's CEO, Dr. Mark Goldsmith, highlighted the progress of RMC-6236, noting its advancement into a pivotal Phase 3 trial for metastatic PDAC and a planned Phase 3 study for NSCLC in early 2025. Revolution Medicines maintains a strong cash position of $1.55 billion, expected to fund operations into 2027, despite reporting a net loss of $156.3 million in the third quarter.
